338 related articles for article (PubMed ID: 21719292)
1. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
Kashihara K; Shinya T; Higaki F
J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
[TBL] [Abstract][Full Text] [Related]
2. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
[TBL] [Abstract][Full Text] [Related]
3. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
[TBL] [Abstract][Full Text] [Related]
4. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.
Kashihara K; Shinya T; Higaki F
Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326
[TBL] [Abstract][Full Text] [Related]
5. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
[TBL] [Abstract][Full Text] [Related]
6. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
[TBL] [Abstract][Full Text] [Related]
7. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
Martin WR; Wieler M; Gee M
Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
[TBL] [Abstract][Full Text] [Related]
8. Use of neuromelanin-sensitive MRI to distinguish schizophrenic and depressive patients and healthy individuals based on signal alterations in the substantia nigra and locus ceruleus.
Shibata E; Sasaki M; Tohyama K; Otsuka K; Endoh J; Terayama Y; Sakai A
Biol Psychiatry; 2008 Sep; 64(5):401-6. PubMed ID: 18452894
[TBL] [Abstract][Full Text] [Related]
9. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
12. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
[TBL] [Abstract][Full Text] [Related]
13. Regional nigral neuromelanin degeneration in asymptomatic leucine-rich repeat kinase 2 gene carrier using MRI.
Gao L; Gaurav R; Ziegner P; Ma J; Sun J; Chen J; Fang J; Fan Y; Bao Y; Zhang D; Chan P; Yang Q; Fan Z; Lehéricy S; Wu T
Sci Rep; 2024 May; 14(1):10621. PubMed ID: 38729969
[TBL] [Abstract][Full Text] [Related]
14. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
[TBL] [Abstract][Full Text] [Related]
15. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease.
Ogisu K; Kudo K; Sasaki M; Sakushima K; Yabe I; Sasaki H; Terae S; Nakanishi M; Shirato H
Neuroradiology; 2013 Jun; 55(6):719-24. PubMed ID: 23525598
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
[TBL] [Abstract][Full Text] [Related]
17. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
[TBL] [Abstract][Full Text] [Related]
18. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
[TBL] [Abstract][Full Text] [Related]
19. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
[TBL] [Abstract][Full Text] [Related]
20. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
